제일파마홀딩스

002620KOSPI

65.0 / 100

Reference Date: 2026-09-08

Financial Score28.5 / 40

News Sentiment12.5 / 25

Momentum14.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Jeil Pharma Holdings was formed through a corporate split in 2017, operating as a holding company overseeing investments, while its subsidiary Jeil Pharmaceuticals focuses on pharmaceutical manufacturing and sales. Key subsidiaries include Jeil Health Sciences (general pharmaceuticals) and Jeil & Partners (sales agency), with major products such as Lipito, Lyrica, and Kepentec. The company's core businesses include management consulting, leasing, investment income, and pharmaceutical sales.

Number of Employees

40people

Average Salary

73.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

3.51Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR

0.26Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

7.64Industry Average 8.002.5Point

Below industry avg

Debt Ratio

18.01Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼9.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲139.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -3.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (44%)

Current 7,610Won52-week high 9,28052-week low 6,290

1-month return3.0Point

1m 0.13% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral반기보고서 (2026.06)2026-08-14
Neutral[기재정정]반기보고서 (2026.06)2026-08-14